BST02 Receives FDA Fast Track Designation in Liver Cancer Management

News
Article

Investigators are assessing the safety, tolerability, and initial efficacy of BST02 in those with advanced or metastatic liver cancer as part of a phase 1 trial.

Developers are assessing the safety, tolerability, and preliminary efficacy of BST02 in patients with locally advanced or metastatic liver cancer in an investigator-initiated phase 1 trial (NCT06173726).

Developers are assessing the safety, tolerability, and preliminary efficacy of BST02 in patients with locally advanced or metastatic liver cancer in an investigator-initiated phase 1 trial (NCT06173726).

The FDA has granted fast track designation to the investigational T-cell therapy BST02 as a treatment for patients with liver cancer, according to a press release from Biosyngen.1

The regulatory agency’s designation for the investigational agent extends to all types of liver cancer, which includes those with hepatocellular carcinoma (HCC) and cholangiocarcinoma. Compared with other tumor-infiltrating lymphocyte (TIL)–based therapies, BST02 is believed to alleviate distance restrictions with its cryopreserved form and reduce the need for high interleukin-2 (IL-2) doses.

Previously, the FDA cleared an investigational new drug (IND) application for the evaluation of BST02 as a treatment for those with liver cancer as part of a phase 1/2 trial in October 2023.2 Additionally, the China National Drug Administration’s Center for Drug Evaluation approved the agent in January 2024.1 According to the press release, these designations mark BST02 as the first TIL cell therapy in the management of liver cancer to advance to the clinical stage on an international scale.

Michelle Chan, co-founder and chief executive officer at Biosyngen, “expressed gratitude” for the FDA’s fast track designation and stated that her company was committed to “advancing cell therapy for cancer globally and providing innovative treatment solutions for diverse patient populations.”1 Moreover, she underscored that developers aim to leverage their “advanced technology platforms to offer more effective and accessible treatment options for patients worldwide.”

Developers are assessing the safety, tolerability, and preliminary efficacy of BST02 in patients with locally advanced or metastatic liver cancer in an investigator-initiated phase 1 trial (NCT06173726). The study will include a dose-escalation and dose-expansion portion to determine how different IL-2 injection doses impact the efficacy and safety of BST02 in the aforementioned population.

Before administering BST02 as an injection, investigators will treat patients with cyclophosphamide at 250 mg or 1.5 g/m2 as a single intravenous infusion.

The trial’s primary end point is the occurrence and incidence of adverse effects (AEs). Other primary end points include serious AEs and dose-limiting toxicities.

Patients 18 to 75 years old with histologically or cytologically confirmed locally advanced or metastatic liver cancer—including those with stage B or C HCC and cholangiocarcinoma not suitable for local treatment based on Barcelona Clinic Liver Cancer criteria—are able to enroll on the trial. Additional eligibility criteria include having at least 1 operation without radiation or other local treatment within 4 weeks of entry to remove the tumor lesion, 1 or more measurable lesions based on RECIST v1.1 guidelines, an ECOG performance status of 0 or 1, a Child-Pugh cirrhosis score of no higher than 7 points, and a life expectancy of at least 3 months. Patients are also required to have adequate organ and bone marrow function within 2 weeks before TIL sampling to enroll.

Those with prior organ transplantation or hematopoietic stem cell transplantation or treatment with immunosuppressive agents within 4 weeks prior to tumor tissue sampling are ineligible to enroll on the trial. Patients are also unsuitable for enrollment if they have received a live vaccine within 3 months of screening or prior major surgery within 4 weeks before entry.

Previously, the FDA granted fast track designation to Biosyngen’s first-in-class immunotherapy BRG01 as a treatment for those with relapsed or metastatic nasopharyngeal carcinoma in July 2023.3 The modified T-cell therapy was designed to expand ex vivo and bind to specific antigens on cancer cells following intravenous administration, thereby mediating the killing of tumors.

References

  1. Biosyngen announces FDA fast track designation for BST02 in treatment of liver cancer. News release. Biosyngen. February 1, 2024. Accessed February 2, 2024. http://tinyurl.com/58am9uah
  2. Biosyngen's BST02, the world's first TIL therapy for liver cancer, is granted an IND approval by FDA. News release. Biosyngen. October 26, 2023. Accessed February 2, 2024. http://tinyurl.com/532trzx9
  3. Biosyngen's first-in-class cell therapy BRG01 receives FDA fast track designation. News release. Biosyngen. July 12, 2023. Accessed February 2, 2024. http://tinyurl.com/mr96h4ka

Related Videos
Adding radiation to sorafenib elicited a survival improvement in a group of patients with hepatocellular carcinoma, a type of liver cancer.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
The combination of tremelimumab plus durvalumab improved survival for patients with unresectable hepatocellular carcinoma in the phase 3 HIMALAYA trial.
Ghassan K. Abou-Alfa, MD, examined the trial design of the phase 3 HIMALAYA trial of tremelimumab plus durvalumab for frontline hepatocellular carcinoma, with results presented at the 2022 Gastrointestinal Cancers Symposium.
Ghassan K. Abou-Alfa, MD, detailed the evolution of treatment options for unresectable hepatocellular carcinoma prior to the phase 3 HIMALAYA study and the reasons for launching the trial.
Related Content